Nice post, thsloppy, and I might well agree with your assessment of MNKD as a once in a lifetime opportunity, except for the funding deficit. It really is a significant cloud hanging over this company. It will be interesting to see how management solves this issue, could be very good, or the opposite.

Getting the FDA to approve seems like a far easier task than getting to approval with a decent share price. I remain guardedly optimistic that management will do the best they can for all involved, very much including public, non-inside stockholders.